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Although diabetogenic and insulin-like activities are intrinsic properties of the growth hormone (GH) 
molecule, it has been frequently suggested that the hormone must be proteolytically processed for these 
activities to be expressed. If this is correct, then derivatives of GH having resistance to appropriate 
proteolytic attack might not have diabetogenic a n d / o r  insulin-like activity. The purpose of the present study 
was to prepare derivatives of human GH that are resistant to digestion by trypsin and to determine whether 
they possess diabetogenic or insulin-like activity. Three derivatives were prepared from purified native human 
GH in which lysine residues were modified with methyl acetimidate, citraconic anhydride or S-ethyl- 
thioltrifluoroacetate, and one in which arginine residues were modified with camphorquinone-10-sulfonic 
acid. Comparisons of peptide maps of tryptic digests of these derivatives with that of unmodified human GH 
indicated that all four were resistant to proteolysis by trypsin. All of these trypsin-resistant forms of human 
GH were found to possess significant growth-promoting, diabetogenic and insulin-like activities, although all 
activities were attenuated to some extent in each derivative. The relative potencies of the human GH 
derivatives in a radioimmunoassay for human GH were somewhat similar to their order of potency in the 
growth-promoting and diabetogenic assays. These results suggest that if proteolytic processing of the GH 
molecule is involved in the expression of one or more of its biological activities, such processing probably 
does not involve a trypsin-like proteinase. 
Introduction 
Pituitary growth hormone (GH) exhibits several 
distinct biological actions in mammals [1]. In ad- 
dition to growth-promoting activity, GH can be 
diabetogenic, producing hyperinsulinemia, hyper- 
glycemia and glucose intolerance when given in 
doses greater than those required to promote 
growth. In GH-deficient subjects, the hormone 
also exhibits transient insulin-like effects, stimulat- 
ing glucose uptake and utilization by peripheral 
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tissues. It has been suggested that the intact GH 
molecule is not itself diabetogenic, but that it must 
be proteolytically processed in the organism to 
smaller peptides for diabetogenic activity to be- 
come manifest [2]. This concept is supported by 
studies showing that controlled digestion of hu- 
man G H  with pepsin [3,4] produced a product 
capable of causing acute glucose intolerance in the 
genetically obese (ob /ob)  mouse. Additionally, 
Lewis et al. [2] reported that digestion of human 
G H  with subtilisin resulted in a product which 
produced fasting hyperglycemia and glucose in- 
tolerance within 10 h after its administration to 
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dogs, whereas intact human GH was not diabeto- 
genic in this assay. That proteolytic processing 
could also be important for the insulin-like prop- 
erty of GH has been suggested by recent findings 
that a synthetic peptide representing residues 
31-44 of human GH exhibits significant in vitro 
insulin-like activity on glucose uptake by isolated 
rat epididymal adipose tissue [5]. 
If it is indeed correct that proteolytic processing 
of the native GH molecule by the organism is 
required for the expression of diabetogenic activ- 
ity, and perhaps insulin-like activity, then mod- 
ified forms of GH that are resistant to appropriate 
proteolytic attack might not exhibit these activi- 
ties. In the present study, chemical derivatives of 
human GH were prepared in which lysine or 
arginine residues were modified to render the 
molecule more resistant to proteolysis by trypsin. 
The various biological activities of these deriva- 
tives were then characterized. 
Methods 
Native human GH that had been purified as 
previously described [6] and chemically and bio- 
logically characterized in our laboratory was used 
as the precursor for all modified forms, and as the 
reference standard in the various bioassays. It was 
also used to prepare 125I-labeled human GH by 
the lactoperoxidase method of Thorell and Johans- 
son [7]. Citraconic anhydride, methyl acetimidate, 
S-ethylthioltrifluoroacetate and camphorquinone- 
10-sulfonic acid were purchased from Pierce 
Chemical Company, Rockford, IL. 
Three human GH derivatives were prepared 
involving the chemical modification of the e-amino 
groups of lysine residues, as well as the free amino 
group of the N-terminal phenylalanine. Two pre- 
parations were produced by reaction of 20 mg and 
30 mg of human GH with citraconic anhydride [8]. 
Following dialysis and lyophilization, 15.6 and 
29.7 mg, respectively, of citraconylated GH were 
recovered. Samples of one of these preparations 
were submitted to gel filtration on a column of 
Sephacryl S-200 that had been calibrated previ- 
ously with unmodified human GH. The column, 
which had been equilibrated with 0.5% (w/v) am- 
monium bicarbonate, was eluted with the same 
solution, and absorbance of the fractions was 
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monitored at 220 nm. In duplicate experiments, 
citraconylated GH was found to contain approx. 
75% monomeric hormone derivative, judging from 
the absorbance of the peaks having elution volumes 
equivalent to that of monomeric human GH. The 
extent of modification of the hormone was moni- 
tored by polyacrylamide gel electrophoresis [9], 
which indicated that virtually all of the starting 
material had been converted to a more negatively 
charged form. Determination of free amino groups 
in the derivative with 2,4,6-trinitrobenzenesulfonic 
acid [10] indicated that three of the ten free amino 
groups in the molecule had been modified. 
The degree to which the citraconylated GH 
preparations were resistant to proteolytic attack by 
trypsin was determined by comparison of peptide 
maps of tryptic digests of the derivative with that 
of unmodified human GH by a modification of 
the method of Seavey et al. [11]. Digestion of the 
hormones with trypsin (TPCK trypsin, Worthing- 
ton, Freehold, N J) was carried out in 0.5% sodium 
dodecyl sulfate at 37°C for 4 h. The enzyme/  
substrate ratio was 20:1 (w/w). Mapping of the 
digests was performed on 20 x 20 cm plastic thin- 
layer chromatography sheets coated with cellulose 
(0.1 mm, Pierce Chemical Company Rockford, 
IL). Approx. 200 #g of digest were applied to the 
thin-layer sheet, and ascending chromatography 
was then performed in the first dimension with 
n-butyl alcohol/glacial acetic ac id /pyr id ine /  
water (15 : 3 : 12 : 10). Electrophoresis was carried 
out in buffer containing glacial acetic ac id /  
pyr idine/acetone/water  (2 : 1 : 8 : 40), pH 4.4, for 
1.5 h at 25 V/cm.  Peptides were detected by 
spraying the sheet with 0.001% fluoran/0.01% 
pyridine in acetone and examining it under ultra- 
violet light. Fig. 1 shows typical tryptic peptide 
maps of unmodified human GH and citracony- 
lated GH. It can be seen that trypsin digestion of 
human GH results in the production of numerous 
small peptides, as expected. When the tryptic 
peptide map of citraconylated GH is compared 
with that of unmodified human GH, however, it is 
apparent that modification of the lysine residues 
with citraconic anhydride rendered the hormone 
resistant to proteolytic attack by trypsin, judging 
from the reduction in the number of cleavage 
products produced and alterations in their electro- 
phoretic mobilities. 
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Fig. 1. Peptide maps of trypsin digests of unmodified human 
GH (AL citraconylated GH (B), amidinated GH (C), trifluoro- 
acetylated GH (D) and camphorquinone-10-sulfonic acid-mod- 
ified GH (E). The dotted shapes indicate weakly staining 
peptides. ( - ) indicates the cathode. 
Two preparations of amidinated G H  were pro- 
duced by reaction of 30 and 20 mg of native 
human G H  with methyl acetimidate [12]. Follow- 
ing dialysis and lyophilization, 23.5 and 18.1 mg, 
respectively, of amidinated G H  were recovered. 
These preparations were subjected to gel filtration 
on a column of Sephacryl S-200 that had been 
equilibrated with 0.5% (w/v)  ammonium bi- 
carbonate and found to contain approx. 75% 
monomeric hormone derivative. The fractions rep- 
resenting monomer were pooled and lyophilized, 
yielding 12.0 and 12.8 mg, respectively, of mono- 
meric amidinated GH. The extent of modification 
of the amidinated G H  preparations was monitored 
by amino acid analysis [9], which revealed the 
emergence of a peak which was presumed to repre- 
sent amidinated lysine residues. The calculated 
mole percentage of this peak was equivalent to the 
mole percent that was lost from the lysine peak 
and suggested four or five of the nine lysine re- 
sidues had been amidinated (data not shown). As 
shown in Fig. 1, it is apparent that amidination of 
human G H  rendered the hormone molecule re- 
sistant to digestion by trypsin. 
One preparation of modified human G H  was 
produced in which the terminal amino group and 
the e-amino groups of lysine residues were trifluo- 
roacetylated [13]. This derivative was prepared by 
reaction of 30 mg of native human G H  with 
S-ethylthioltrifluoroacetate. Following dialysis and 
lyophilization, 19 mg of trifluoroacetylated G H  
were recovered. When samples of trifluoro- 
acetylated G H  were submitted to polyacrylamide 
gel electrophoresis, no indication of starting 
material was observed on the gels. Estimation of 
free amino groups in the derivative with 2,4,6-tri- 
nitrobenzenesulfonic acid indicated that six amino 
groups had been trifluoracetylated. As is again 
shown in Fig. 1, trifluoroacetylated G H  exhibited 
resistance to proteolytic attack by trypsin, judging 
from the reduced number of digestion products 
detected. 
Finally, two hormone preparations were pro- 
duced in which the arginine residues were mod- 
ified by reaction of 20 and 30 mg of native human 
G H  with camphorquinone-10-sulfonic acid [14]. 
Following dialysis and lyophilization, 16.0 and 
25.8 mg, respectively, of camphorquinone-10- 
sulfonic acid-modified G H  were recovered. When 
one of these preparations was subjected to gel 
filtration on a column of Sephacryl S-200 that had 
been equilibrated with 0.5% (w/v)  ammonium bi- 
carbonate, it was found to contain approx. 80% 
monomeric hormone derivative (data not shown). 
Polyacrylamide gel electrophoresis of these pre- 
parations revealed a poorly staining, more acidic 
band with no evidence of remaining starting 
material (data not shown). Again, as shown in Fig. 
1, modification of arginine residues with camphor- 
quinone-10-sulfonic acid rendered the resulting 
hormone derivative resistant to proteolytic attack 
by trypsin. 
The bioassays used to assess the growth-prom- 
iting activity [15], diabetogenic activity [16] and in 
vitro insulin-like activity [9] of the modified G H  
preparations have been described in detail. All 
modified G H  preparations were also tested for 
their ability to compete with ~25I-labeled human 
G H  for binding to guinea pig antiserum to human 
G H  as previously described [15]. 
Results 
The growth-promoting activities of the mod- 
ified G H  preparations and the native human G H  
which served as precursor were assessed in the 
9-day weight-gain test in hypophysectomized rats 
and compared to the International Standard of 
GH,  Bovine (defined as 1.0 I U / m g ) .  In this assay, 
the G H  preparations were injected subcutaneously 
once daily for 9 days at the following daily doses 
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TABLE I 
G R O W T H - P R O M O T I N G  POTENCIES OF TRYPSIN-RE- 
SISTANT H U M A N  GH PREPARATIONS 
Values were estimated in the 9-day weight-gain test in hypo- 
physectomized rats using the International Standard of Growth 
Hormone,  Bovine (1.0 I U / m g )  as the standard. Potency esti- 
mates are shown with their 95% confidence limits given in 
parentheses. CQSA, camphorquinone-10-sutfonic acid. 
Material Growth-promoting potency 
( I U / m g )  







1.22 (0.9-1.8) a 
0.43 (0.2-0.7) 
0.29 (0.02-0.78) 
a Pooled estimate for two assays. 
(number of rats used per dose are given in 
parentheses): bovine GH standard, 20/~g (5) and 
100/~g (5); unmodified human GH, 10 t~g (4) and 
50 t~g (5); amidinated GH, 10 #g (4) and 50 /~g 
(5); citraconylated GH, 20/~g (8) and 100 ~g (7); 
trifluoroacetylated GH, 20/~g (5) and 100/~g (5); 
and camphorquinone-10-sulfonic acid-modified 
GH, 20 ~g (4) and 100 t~g (4). As shown in Table 
I, both amidinated GH and citraconylated GH 
retained substantial growth-promoting activity, 
having estimated potencies greater than 1 IU/mg.  
In contrast, the growth-promoting potency of tri- 
fluoroacetylated GH, in which lysine residues are 
also modified was markedly reduced. Whether the 
reduced growth-promoting activity of trifluoro- 
acetylated GH is due to the introduction of triflu- 
oroacetyl groups in the molecule or to its reduced 
water solubility compared to that of unmodified 
human GH remains.to be established. It can be 
seen in Table I that camphorquinone-10-sulfonic 
acid-modified GH, in which arginines have been 
modified, also possessed reduced but significant 
growth-promoting activity. 
The human GH derivatives were tested for di- 
abetogenic activity in the genetically obese (ob/ob) 
mouse by their ability to increase fasting blood 
glucose concentration and decrease glucose toler- 
ance when administered chronically. Groups of 
ob/ob mice (5 6 months of age) were injected 
subcutaneously with saline for 3 consecutive days, 
and on the fourth day a control glucose tolerance 
test was performed [16]. 7 days after the beginning 
of saline treatment, the same mice were injected 
with the test substance for 3 days, and on the 
fourth day the tolerance test was repeated. Results 
obtained when native GH was administered at 
doses of 5, 10 or 25 /~g/day for 3 days are 
depicted in Fig. 2. It can be seen that unmodified 
human GH at a dose of 5 /zg/day had no effect 
on fasting blood glucose concentration or glucose 
tolerance. However, a significant increase in fast- 
ing blood glucose concentration and decreased 
glucose tolerance were produced when the dose of 
hormone was increased to 10 /~g/day. A very 
marked diabetogenic response was produced with 
a dose of 25 /~g/day of unmodified human GH. 
Fig. 3 shows the results obtained when amidinated 
GH was tested for diabetogenic activity in this 
assay. A dose of 5/~g/day of amidinated GH had 
little effect on fasting blood glucose concentration 
and glucose tolerance, whereas a dose of 25/~g/day 
produced marked effects on both. Thus, when 
compared to native human GH, amidinated GH 
appears to retain high diabetogenic activity. When 
citraconylated GH was tested in this assay (see 
Fig. 4), a dose of 25 /~g/day produced a slight 
effect on fasting blood glucose concentration but 
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Fig. 2. Effects of treatment with three doses 
of unmodified human GH for 3 days on 
glucose tolerance of o b / o b  mice. Each point 
represents the mean of n observations. Verti- 
cal lines through the points indicate 2 S.E. 
The effects of the 10 /~g /day  and 25 /xg /day  
doses of hormone were significant (P  < 0.05) 
by paired t test at all time points examined. 
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Fig. 3. Effects of treatment with two doses of amidinated GH 
for 3 days on glucose tolerance of o b / o b  mice. Each point 
represents the mean of n observations. Vertical lines through 
the points indicate 2 S.E. The effects of the 5 ~ g / d a y  dose of 
amidinated GH were statistically significant ( P < 0.05) at the 0 
a n d  30 min time points. The effects of the 25 f ig /day  dose were 
statistically significant (P  < 0.05) at all time points examined. 
of citraconylated GH was raised to 50 /~g/day a 
very marked increase in fasting blood glucose con- 
centration and decrease in glucose tolerance were 
obtained. Thus, citraconylated GH appears to re- 
tain 10-20% the diabetogenic activity of unmod- 
ified human GH in this assay. The diabetogenic 
activity of trifluoracetylated GH is depicted in 
Fig. 5. It can be seen that no activity was detected 
when the derivative was tested at a dose of 50 
F g / d a y ,  but a large diabetogenic response was 
obtained when the dose was raised to 250 Fg /day .  
Thus, it appears to retain 5-10% the diabetogenic 
activity of the native hormone. Rather similar 
results were obtained with camphorquinone-10- 
sulfonic acid-modified GH (see Fig. 6). A dose of 
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Fig. 5. Effects of treatment with two doses of trifluoro- 
acetylated GH for 3 days on glucose tolerance of o b / o b  mice. 
Each point represents the mean of n observations. Vertical 
lines through the points indicate 2 S.E. The effects of the 250 
f ig /day  dose of trifluoroacetylated GH were statistically sig- 
nificant at all time points examined. 
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Fig. 4.  Effects of treatment with two doses of citraconylated 
GH for 3 days on glucose tolerance of o b / o b  mice. Each point 
represents the mean of n observations. Vertical lines through 
the points indicate 2 S.E. The effects of the 25 f ig /day  dose of 
citraconylated GH were only statistically significant (P  < 0.05) 
at the 0 rain time point. The effects of the 50 f ig /day  dose of 
hormone derivative were significant at all time points ex- 
amined. 
effect on fasting blood glucose but had no effect 
on glucose tolerance. When the dose was raised to 
250 # g / d a y ,  marked effects on fasting blood glu- 
cose concentration and glucose tolerance were 
noted. Thus, this arginine-modified form of hu- 
man GH retained approx. 5-10% of the diabeto- 
genic activity of native human GH. 
Insulin-like activity of the trypsin-resistant hu- 
man GH derivatives was assessed by their in vitro 
ability to stimulate [t4C]glucose oxidation to MCO2 
by isolated epididymal adipose tissue of hypo- 
physectomized rats. The results obtained are sum- 
marized in Table II. Unmodified human GH pro- 
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Fig. 6. Effects of treatment with two doses of camphorquinone-  
10-sulfonic acid-modified GH for 3 days on glucose tolerance 
of o b / o b  mice. Each point represents the mean of n observa- 
tions. Vertical lines through the points indicate 2 S.E. The 
effects of the 50 /~g /day  dose of hormone derivative were only 
statistically significant at the 0 rain time point. The effects of 




IN VITRO EFFECTS OF TRYPSIN-RESISTANT HUMAN GH PREPARATIONS ON GLUCOSE OXIDATION BY EPIDIDY- 
MAL ADIPOSE TISSUE OF HYPOPHYSECTOMIZED RATS 
Segments of epididymal adipose tissue were incubated for 60 min at 37°C in medium containing [14C]glucose with or without the 
indicated concentration of test substance. 14CO2 production values represent the means_+ S.E. of n observations. CQSA, camphor- 
quinone-10-sulfonic acid. 
Material Concn. n 
(nM) 
14C02 production (dpm/mg per h) 
control hormone 
Unmodified human GH 2 7 47.8 +_ 5.5 66.8 +_ 7.5 
20 7 47.8_+5.5 85.0_+ 4.9 a 
Amidinated GH 2 7 47.8 ___ 5.5 59.5 + 6.2 
20 7 47.8 _+ 5.5 79.1 _+ 10.0 ~ 
Unmodified human GH 2.5 16 65.5 _+ 8.6 106.2.+ 15.5 
25 16 65.5 .+ 8.6 156.8 .+ 21.4 a 
Citraconylated GH 25 16 65.5 .+ 8.6 134.3 .+ 18.2 a 
250 16 65.5 + 8.6 165.5 + 21.6 ~ 
Unmodified GH 2.5 8 73.3 -+ 9.9 135.4 -+ 11.3 a 
25 8 73.3 + 9.9 196.4-+ 22.3 ~ 
Trifluoroacetylated GH 25 8 73.3 _+ 9.9 108.1 +_ 17.2 
250 8 73.3 +_ 9.9 160.4 .+ 26.6 ~ 
Unmodified GH 5 8 49.0 .+ 4.0 82.5 .+ 9.9 a 
25 8 49.0_+4.0 105.5 _+ 11.6 a 
CQSA-modified GH 50 8 49.0 .+ 4.0 77.0 _+ 11.0 ~ 
250 8 49.0+__4.0 103.9_+ 11.7 a 
a Statistical comparisons were made with Dunnett's test. A difference is considered to be significant when P < 0.05. 
duced statistically significant s t imulatory effects 
on  glucose oxidat ion when employed at concentra-  
t ions of 2 .5-5 n M  in this assay. It can be seen in 
Table  II that amidina ted  G H  and ci traconylated 
G H  retained substant ia l  activity in this assay, 
whereas trif luoracetylated G H  and  camphorqui-  
none-10-sulfonic  acid-modified G H  appeared to 
have approx. 10% the activity of native h u m a n  
GH.  
Finally,  the trypsin-resistant  derivatives of hu- 
man  G H  were tested for their abili ty to compete 
with t25I-labeled h u m a n  G H  for b ind ing  to anti-  
bodies to h u m a n  GH.  The potencies of the deriva- 
tives in this assay relative to that of unmodif ied  
h u m a n  G H  were estimated by determining the 
amoun t  of test substance required to displace 50% 
of an t ibody-bound  t25I-labeled human  GH.  All 
displacement  curves obta ined with the derivatives 
were parallel  to that produced with unmodif ied  
h u m a n  GH.  Assuming a potency of 100% for 
unmodif ied  h u m a n  GH,  the following relative 
potencies (+S .E . )  were estimated from repeated 
(2-6)  assays: amidina ted  GH,  90.5 _+ 3.8; citra- 
conylated GH,  71.5 _+ 3.1; trifluroacetylated GH,  
40.0; and camphorquinone-10-sul fonic  acid-mod- 
ified GH,  43.3 + 3.3. Thus, the relative potencies 
of the derivatives in this assay are somewhat simi- 
lar to their order of potency in the growth-promo- 
t ing and diabetogenic assays. 
Discussion 
In  the present  study, four derivatives of G H  
were prepared in which lysine or arginine residues 
were modified chemically to render  the hormone  
molecule more resistant to proteolysis by trypsin. 
All of these trypsin-resistant  forms of h u m a n  G H  
were found to possess significant growth-promo- 
ting, diabetogenic and insulin-l ike activities, al- 
though all activities were a t tenuated to some ex- 
tent  in each derivative. Of the four derivatives 
studied, amidina ted  GH,  in which positive charges 
on lysine residues were retained, was the most 
active, having nearly full growth-promoting activ- 
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ity and a high degree of diabetogenic and insulin- 
like activities. This finding is in agreement with a 
recent report by de Satz and Santome [17], indicat- 
ing that bovine GH, in which four or five of the 
lysine residues were amidinated, retained essen- 
tially full growth-promoting activity. As these 
authors suggested, retention of a positive charge 
on certain lysine residues in GH may be important 
for the expression of high biological activity. 
Citraconylated GH, in which negatively charged 
groups were present on certain lysine residues, 
retained substantial growth-promoting and in- 
sulin-like activities, but its diabetogenic activity 
was reduced. All activities were substantially at- 
tenuated in the trifluoroacetylated derivative being 
approx. 10% those of the native hormone. The 
arginine-modified derivative also exhibited a sig- 
nificant but attenuated biological activity profile. 
From these observations, it would seem reasonable 
to conclude that the alterations in biological activ- 
ity profile exhibited by the various derivatives are 
not due to their trypsin-resistance but are most 
likely due to changes in configuration of the 
hormone molecule resulting from the chemical 
modification of the lysine and arginine residues. If 
proteolytic processing of the GH molecule is 
involved in the expression of one or more of its 
biological activities, such processing probably does 
not involve a trypsin-like proteinase. 
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